Form 4: Solen Therapeutics CEO Anish Bhatnagar Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Anish Bhatnagar, CEO of Soleno Therapeutics, sold shares of common stock on April 1, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- On April 1, 2024, Anish Bhatnagar, the CEO of Soleno Therapeutics, sold shares of the company's common stock.
- The sales were executed in multiple trades at weighted average prices of $41.1227 and $41.6671.
- A total of 11,383 shares were sold at the first weighted average price and 7,597 shares at the second.
- These transactions were conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- Following the reported transactions, Bhatnagar still beneficially owns 152,790 shares of Soleno Therapeutics common stock, some of which are RSUs.
Sentiment
Score: 5
Explanation: The document simply reports a routine stock sale for tax purposes, indicating a neutral sentiment.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives.
Stakeholder Impact
- The stock sale may have a minor, temporary impact on shareholders due to the increased supply of shares in the market.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of stock sale transactions. |
| 04/03/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.